Chimeric antigen receptors (CARs) are receptors for antigen that direct potent immune responses. Tumor escape associated with low target antigen expression is emerging as one potential limitation of their efficacy. Here we edit the TRAC locus in human peripheral blood T cells to engage cell-surface targets through their T cell receptor-CD3 complex reconfigured to utilize the same immunoglobulin heavy and light chains as a matched CAR. We demonstrate that these HLA-independent T cell receptors (HIT receptors) consistently afford high antigen sensitivity and mediate tumor recognition beyond what CD28-based CARs, the most sensitive design to date, can provide. We demonstrate that the functional persistence of HIT T cells can be augmented by co...
ABSTRACT Adoptive immunotherapies composed of T cells engineered to express a chimeric antigen recep...
T-cell receptors (TCR) recognize intracellular and extracellular cancer antigens, allowing T cells t...
Abstract Effector T cells equipped with engineered antigen receptors specific for cancer targets hav...
One important purpose of T cell engineering is to generate tumor-targeted T cells through the geneti...
Insufficient reactivity against cells with low antigen density has emerged as an important cause of ...
Adoptive T cell therapies have achieved significant clinical responses, especially in hematopoietic ...
© 2014 Dr. Connie DuongAdoptive immunotherapy is a promising treatment for cancer, with response rat...
The expression of synthetic receptors in primary T cells enables the programming of user-defined res...
Chimeric antigen receptors (CARs) are versatile synthetic receptors that provide T cells with engine...
Purpose: Targeting nonspecific, tumor-associated antigens (TAA) with chimeric antigen receptors (CAR...
BACKGROUND: Chimeric antigen receptor (CAR) T cell therapy has proven its clinical utility in hemato...
BackgroundT cells expressing chimeric antigen receptors (CARs) have shown exciting promise in cancer...
Chimeric antigen receptors (CARs) can effectively redirect cytotoxic T cells toward highly expressed...
Background Chimeric antigen receptor (CAR) T cell therapy has proven its clinical utility in hematol...
Background: T cells expressing chimeric antigen receptors (CARs) have shown exciting promise in canc...
ABSTRACT Adoptive immunotherapies composed of T cells engineered to express a chimeric antigen recep...
T-cell receptors (TCR) recognize intracellular and extracellular cancer antigens, allowing T cells t...
Abstract Effector T cells equipped with engineered antigen receptors specific for cancer targets hav...
One important purpose of T cell engineering is to generate tumor-targeted T cells through the geneti...
Insufficient reactivity against cells with low antigen density has emerged as an important cause of ...
Adoptive T cell therapies have achieved significant clinical responses, especially in hematopoietic ...
© 2014 Dr. Connie DuongAdoptive immunotherapy is a promising treatment for cancer, with response rat...
The expression of synthetic receptors in primary T cells enables the programming of user-defined res...
Chimeric antigen receptors (CARs) are versatile synthetic receptors that provide T cells with engine...
Purpose: Targeting nonspecific, tumor-associated antigens (TAA) with chimeric antigen receptors (CAR...
BACKGROUND: Chimeric antigen receptor (CAR) T cell therapy has proven its clinical utility in hemato...
BackgroundT cells expressing chimeric antigen receptors (CARs) have shown exciting promise in cancer...
Chimeric antigen receptors (CARs) can effectively redirect cytotoxic T cells toward highly expressed...
Background Chimeric antigen receptor (CAR) T cell therapy has proven its clinical utility in hematol...
Background: T cells expressing chimeric antigen receptors (CARs) have shown exciting promise in canc...
ABSTRACT Adoptive immunotherapies composed of T cells engineered to express a chimeric antigen recep...
T-cell receptors (TCR) recognize intracellular and extracellular cancer antigens, allowing T cells t...
Abstract Effector T cells equipped with engineered antigen receptors specific for cancer targets hav...